Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Paweł Moćko is active.

Publication


Featured researches published by Paweł Moćko.


Pharmacological Reports | 2016

Safety profile of biologic drugs in the therapy of Crohn disease: A systematic review and network meta-analysis

Paweł Moćko; Paweł Kawalec; Andrzej Pilc

BACKGROUND Crohn disease (CD) is an inflammatory bowel disease which occurs especially in developed countries of Western Europe and North America. The aim of the study was to compare the safety profile of biologic drugs in patients with CD. METHODOLOGY A systematic literature search was performed using PubMed, Embase, and CENTRAL databases, until April 27, 2016. We included randomized controlled trials (RCTs) that compared the safety of biologic drugs (infliximab, adalimumab, vedolizumab, certolizumab pegol, and ustekinumab) with one another or with placebo in patients with CD. The network meta-analysis (NMA) was conducted for an induction phase (6-10 weeks) and maintenance phase (52-56 weeks) with a Bayesian hierarchical random effects model in the ADDIS® software. The PROSPERO registration number was CRD42016032606. RESULTS Ten RCTs were included in the systematic review with NMA. In the case of the induction phase, the NMA could be conducted for the assessment of the relative safety profile of adalimumab, vedolizumab, certolizumab pegol, and ustekinumab, and in the case of the maintenance phase-of infliximab, adalimumab, and vedolizumab. There were no significant differences in the rate of adverse events in patients treated with biologics. Statistical analysis revealed that vedolizumab had the greatest probability of being the safest treatment in most endpoints in the induction phase and adalimumab-in the maintenance phase. CONCLUSIONS No significant differences between the biologics in the relative safety profile analysis were observed. Further studies are needed to confirm our findings, including head-to-head comparisons between the analyzed biologics.


Expert Review of Pharmacoeconomics & Outcomes Research | 2015

The indirect costs of multiple sclerosis: systematic review and meta-analysis

Ewa Stawowczyk; Krzysztof Piotr Malinowski; Paweł Kawalec; Paweł Moćko

The aim of this systematic review is to collect and summarize all current data on the indirect costs related to absenteeism and presenteeism associated with multiple sclerosis. Searches were conducted using Medline, Embase and Centre for Reviews and Dissemination databases. All collected costs were recalculated to average annual cost per patient, expressed in 2014 prices US


Archives of Medical Science | 2016

Effectiveness and safety of vedolizumab for treatment of Crohn’s disease: a systematic review and meta-analysis

Paweł Moćko; Paweł Kawalec; Beata Smela-Lipińska; Andrzej Pilc

using the consumer price index and purchasing power parity (scenario 1) and expressed as proportion of specific gross domestic product in current local currency unit to adjust for country’s development (scenario 2). Identified studies were then analyzed in order to assess their possible inclusion in the meta-analysis. The authors identified 63 records, of which 23 were eligible for meta-analysis. Overall indirect cost per patient calculated in scenario 1 was as high as US


Journal of Comparative Effectiveness Research | 2017

Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis

Paweł Kawalec; Paweł Moćko; Iwona Malinowska-Lipień; Tomasz Brzostek

20,167 with US


Pharmacotherapy | 2016

Vedolizumab Compared with Certolizumab in the Therapy of Crohn Disease: A Systematic Review and Indirect Comparison.

Paweł Kawalec; Paweł Moćko; Andrzej Pilc; Maria Radziwon-Zalewska; Iwona Malinowska-Lipień

22,197 in Europe, US


Expert Review of Pharmacoeconomics & Outcomes Research | 2016

Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland

Krzysztof Piotr Malinowski; Paweł Kawalec; Paweł Moćko

17,382 in North America and US


Zdrowie Publiczne i Zarządzanie | 2016

Analysis of costs of diabetes in Poland in 2012 and 2013

Paweł Moćko; Paweł Kawalec; Krzysztof Piotr Malinowski

153 in Asia. Overall indirect cost per patient calculated in scenario 2 was equal to US


Journal of Comparative Effectiveness Research | 2018

An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients

Paweł Kawalec; Paweł Moćko

16,939, with US


Medycyna Rodzinna | 2016

Biological drugs in the treatment of ankylosing spondylitis (AS) – systematic review

Paweł Moćko; Paweł Kawalec; Katarzyna Antoniewicz; Andrzej Pilc

19,612 in Europe, US


Medycyna Rodzinna | 2016

Inflammatory bowel diseases (IBD) as public health problem – review of the literature

Paweł Moćko; Paweł Kawalec; Andrzej Pilc

11,592 in North America and US

Collaboration


Dive into the Paweł Moćko's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Andrzej Pilc

Polish Academy of Sciences

View shared research outputs
Top Co-Authors

Avatar

Krzysztof Piotr Malinowski

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Ewa Stawowczyk

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Iwona Malinowska-Lipień

Jagiellonian University Medical College

View shared research outputs
Top Co-Authors

Avatar

Tomasz Brzostek

Jagiellonian University Medical College

View shared research outputs
Researchain Logo
Decentralizing Knowledge